' 
SCIENTIFIC SCORE
Moderately Effective
Based on 4 Researches
8.5
USERS' SCORE
Good
Based on 3 Reviews
8.6
Supplement Facts
Serving Size: 3 Softgels
Amount Per Serving
%DV
Calories
20
Total Fat
2 g
3%**
Total Carbohydrate
2 g
1%**
Protein
less than 1 g
Reducol Plant sterols/stanols (as esters)††
900 mg
*
Pantethine (Pantesin)
300 mg
*
Top Medical Research Studies
9
MEDI0618 shows promise for migraines
Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine.
Direct evaluation of monoclonal antibody
We observed the potential of MEDI0618, a targeted monoclonal antibody, in treating migraine by focusing on a receptor known as protease-activated receptor 2 (PAR2). This study analyzed how the antibody impacted migraine-like symptoms in various preclinical models, including both human and rodent systems.
Through a series of experiments, we found that MEDI0618 demonstrated a strong binding ability to human PAR2, effectively preventing increases in cell calcium levels triggered by certain enzymes. This suggests that MEDI0618 could play a key role in blocking pain mechanisms associated with migraine without affecting other related receptors.
The antibody was tested in several conditions simulating migraine pain, involving both chemical triggers and stress. Remarkably, MEDI0618 was effective in reducing headache-like pain across various models, including those not dependent on CGRP (calcitonin gene-related peptide), which is typically targeted in migraine therapies.
Although the findings are promising for the prevention of migraine attacks, it's important to note that MEDI0618 did not show effectiveness in alleviating post-traumatic headache pain from brain injury. Overall, this research highlights MEDI0618 as a potentially innovative treatment option for people suffering from migraines, especially those experiencing CGRP-independent episodes.
Through a series of experiments, we found that MEDI0618 demonstrated a strong binding ability to human PAR2, effectively preventing increases in cell calcium levels triggered by certain enzymes. This suggests that MEDI0618 could play a key role in blocking pain mechanisms associated with migraine without affecting other related receptors.
The antibody was tested in several conditions simulating migraine pain, involving both chemical triggers and stress. Remarkably, MEDI0618 was effective in reducing headache-like pain across various models, including those not dependent on CGRP (calcitonin gene-related peptide), which is typically targeted in migraine therapies.
Although the findings are promising for the prevention of migraine attacks, it's important to note that MEDI0618 did not show effectiveness in alleviating post-traumatic headache pain from brain injury. Overall, this research highlights MEDI0618 as a potentially innovative treatment option for people suffering from migraines, especially those experiencing CGRP-independent episodes.
Read More
9
Galectin-1's role in migraines
Galectin-1 Regulates Inflammatory Responses and Promotes Microglial M2 Polarization in Chronic Migraine.
Highly relevant to migraine therapy
We investigated the role of galectin-1, a protein known for its anti-inflammatory properties, in the context of chronic migraine (CM). Through a combination of patient data and a nitroglycerin-induced mouse model, we observed that levels of galectin-1 were significantly lower in CM patients compared to healthy individuals.
Additionally, we found that these lower levels of galectin-1 correlated with higher scores on pain and disability assessments, indicating a possible link between this protein and the severity of migraine symptoms. As part of our research, we also noted that CM patients had increased markers of inflammation and decreased indicators of anti-inflammatory response.
When we supplemented galectin-1 in the mouse model, we saw impressive results. The treatment not only reduced the animals' pain responses but also appears to have helped shift microglia—the brain's immune cells—toward a more anti-inflammatory state. This shift was accompanied by lower levels of pro-inflammatory signals and increased levels of protective cytokines.
The study suggests that enhancing galectin-1 could be a promising new approach to alleviate migraine symptoms and may establish it as a potential therapeutic target for chronic migraine sufferers.
Additionally, we found that these lower levels of galectin-1 correlated with higher scores on pain and disability assessments, indicating a possible link between this protein and the severity of migraine symptoms. As part of our research, we also noted that CM patients had increased markers of inflammation and decreased indicators of anti-inflammatory response.
When we supplemented galectin-1 in the mouse model, we saw impressive results. The treatment not only reduced the animals' pain responses but also appears to have helped shift microglia—the brain's immune cells—toward a more anti-inflammatory state. This shift was accompanied by lower levels of pro-inflammatory signals and increased levels of protective cytokines.
The study suggests that enhancing galectin-1 could be a promising new approach to alleviate migraine symptoms and may establish it as a potential therapeutic target for chronic migraine sufferers.
Read More
8
HIF-1α and migraine connection explored
Association Between Hypoxia-Inducible Factor-1α and Neurological Diseases: A Bidirectional Two-Sample Mendelian Randomization Analysis.
Moderate relevance; need for more clarity
We delved into whether levels of hypoxia-inducible factor 1-α (HIF-1α) in the blood could play a causal role in migraines. Our research utilized a method called Mendelian randomization, drawing on data from genome-wide association studies to explore the relationships between genetic variants that influence HIF-1α and various neurological conditions.
The results were quite revealing. We discovered that higher levels of plasma HIF-1α seem to be linked to a lower risk of experiencing migraines, specifically drug-induced migraines without aura. This finding is intriguing as it points to a potential protective role HIF-1α might play against migraines.
However, it’s important to note that we did not find any significant association between HIF-1α and other types of headaches, including other subtypes of migraines or major neurological diseases like Alzheimer’s and Parkinson’s. Our reverse analysis, which looked at whether migraines could affect HIF-1α levels, showed no causal relationship either.
Overall, what we observed suggests that HIF-1α could open new avenues for understanding migraines and eventually lead to new strategies for prevention and treatment. But as with any scientific exploration, more research is needed to fully grasp these connections and their implications.
The results were quite revealing. We discovered that higher levels of plasma HIF-1α seem to be linked to a lower risk of experiencing migraines, specifically drug-induced migraines without aura. This finding is intriguing as it points to a potential protective role HIF-1α might play against migraines.
However, it’s important to note that we did not find any significant association between HIF-1α and other types of headaches, including other subtypes of migraines or major neurological diseases like Alzheimer’s and Parkinson’s. Our reverse analysis, which looked at whether migraines could affect HIF-1α levels, showed no causal relationship either.
Overall, what we observed suggests that HIF-1α could open new avenues for understanding migraines and eventually lead to new strategies for prevention and treatment. But as with any scientific exploration, more research is needed to fully grasp these connections and their implications.
Read More
Most Useful Reviews
8.8
Reduced migraine severity
I've been taking these for years as directed by my neurologist to reduce the frequency and severity of my migraines. It took a good year to see the effect, but within three months, I also noticed a decrease in my Chronic Fatigue Syndrome symptoms, which was a delightful surprise. It's essential to maintain the regimen to ensure continued migraine relief.
Read More
8.8
Potential migraine relief
Good quality at a reasonable price from a well-known company. I bought from Amazon and it arrived fresh. I wanted to start taking this for my migraine, which I had forgotten about, as well as for hormone-related afib events. So far, it seems to help; I take it with coconut capsules for added fat. I will update my experience.
Read More
8.8
Effective for visual migraines
Positive results for me, though individual experiences may vary. While rigorous studies are ongoing, I believe it's effective for me. Firstly, it helps with lower back muscle pain, and I have noticed fewer occurrences of visual migraines when taking CoQ10. However, results might differ for others.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 4 Researches
8.5
- All Researches
9
MEDI0618 shows promise for migraines
Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine.
Direct evaluation of monoclonal antibody
We observed the potential of MEDI0618, a targeted monoclonal antibody, in treating migraine by focusing on a receptor known as protease-activated receptor 2 (PAR2). This study analyzed how the antibody impacted migraine-like symptoms in various preclinical models, including both human and rodent systems.
Through a series of experiments, we found that MEDI0618 demonstrated a strong binding ability to human PAR2, effectively preventing increases in cell calcium levels triggered by certain enzymes. This suggests that MEDI0618 could play a key role in blocking pain mechanisms associated with migraine without affecting other related receptors.
The antibody was tested in several conditions simulating migraine pain, involving both chemical triggers and stress. Remarkably, MEDI0618 was effective in reducing headache-like pain across various models, including those not dependent on CGRP (calcitonin gene-related peptide), which is typically targeted in migraine therapies.
Although the findings are promising for the prevention of migraine attacks, it's important to note that MEDI0618 did not show effectiveness in alleviating post-traumatic headache pain from brain injury. Overall, this research highlights MEDI0618 as a potentially innovative treatment option for people suffering from migraines, especially those experiencing CGRP-independent episodes.
Through a series of experiments, we found that MEDI0618 demonstrated a strong binding ability to human PAR2, effectively preventing increases in cell calcium levels triggered by certain enzymes. This suggests that MEDI0618 could play a key role in blocking pain mechanisms associated with migraine without affecting other related receptors.
The antibody was tested in several conditions simulating migraine pain, involving both chemical triggers and stress. Remarkably, MEDI0618 was effective in reducing headache-like pain across various models, including those not dependent on CGRP (calcitonin gene-related peptide), which is typically targeted in migraine therapies.
Although the findings are promising for the prevention of migraine attacks, it's important to note that MEDI0618 did not show effectiveness in alleviating post-traumatic headache pain from brain injury. Overall, this research highlights MEDI0618 as a potentially innovative treatment option for people suffering from migraines, especially those experiencing CGRP-independent episodes.
Read More
9
Galectin-1's role in migraines
Galectin-1 Regulates Inflammatory Responses and Promotes Microglial M2 Polarization in Chronic Migraine.
Highly relevant to migraine therapy
We investigated the role of galectin-1, a protein known for its anti-inflammatory properties, in the context of chronic migraine (CM). Through a combination of patient data and a nitroglycerin-induced mouse model, we observed that levels of galectin-1 were significantly lower in CM patients compared to healthy individuals.
Additionally, we found that these lower levels of galectin-1 correlated with higher scores on pain and disability assessments, indicating a possible link between this protein and the severity of migraine symptoms. As part of our research, we also noted that CM patients had increased markers of inflammation and decreased indicators of anti-inflammatory response.
When we supplemented galectin-1 in the mouse model, we saw impressive results. The treatment not only reduced the animals' pain responses but also appears to have helped shift microglia—the brain's immune cells—toward a more anti-inflammatory state. This shift was accompanied by lower levels of pro-inflammatory signals and increased levels of protective cytokines.
The study suggests that enhancing galectin-1 could be a promising new approach to alleviate migraine symptoms and may establish it as a potential therapeutic target for chronic migraine sufferers.
Additionally, we found that these lower levels of galectin-1 correlated with higher scores on pain and disability assessments, indicating a possible link between this protein and the severity of migraine symptoms. As part of our research, we also noted that CM patients had increased markers of inflammation and decreased indicators of anti-inflammatory response.
When we supplemented galectin-1 in the mouse model, we saw impressive results. The treatment not only reduced the animals' pain responses but also appears to have helped shift microglia—the brain's immune cells—toward a more anti-inflammatory state. This shift was accompanied by lower levels of pro-inflammatory signals and increased levels of protective cytokines.
The study suggests that enhancing galectin-1 could be a promising new approach to alleviate migraine symptoms and may establish it as a potential therapeutic target for chronic migraine sufferers.
Read More
8
HIF-1α and migraine connection explored
Association Between Hypoxia-Inducible Factor-1α and Neurological Diseases: A Bidirectional Two-Sample Mendelian Randomization Analysis.
Moderate relevance; need for more clarity
We delved into whether levels of hypoxia-inducible factor 1-α (HIF-1α) in the blood could play a causal role in migraines. Our research utilized a method called Mendelian randomization, drawing on data from genome-wide association studies to explore the relationships between genetic variants that influence HIF-1α and various neurological conditions.
The results were quite revealing. We discovered that higher levels of plasma HIF-1α seem to be linked to a lower risk of experiencing migraines, specifically drug-induced migraines without aura. This finding is intriguing as it points to a potential protective role HIF-1α might play against migraines.
However, it’s important to note that we did not find any significant association between HIF-1α and other types of headaches, including other subtypes of migraines or major neurological diseases like Alzheimer’s and Parkinson’s. Our reverse analysis, which looked at whether migraines could affect HIF-1α levels, showed no causal relationship either.
Overall, what we observed suggests that HIF-1α could open new avenues for understanding migraines and eventually lead to new strategies for prevention and treatment. But as with any scientific exploration, more research is needed to fully grasp these connections and their implications.
The results were quite revealing. We discovered that higher levels of plasma HIF-1α seem to be linked to a lower risk of experiencing migraines, specifically drug-induced migraines without aura. This finding is intriguing as it points to a potential protective role HIF-1α might play against migraines.
However, it’s important to note that we did not find any significant association between HIF-1α and other types of headaches, including other subtypes of migraines or major neurological diseases like Alzheimer’s and Parkinson’s. Our reverse analysis, which looked at whether migraines could affect HIF-1α levels, showed no causal relationship either.
Overall, what we observed suggests that HIF-1α could open new avenues for understanding migraines and eventually lead to new strategies for prevention and treatment. But as with any scientific exploration, more research is needed to fully grasp these connections and their implications.
Read More
8
Botulinum toxins aid migraine relief
Botulinum Neurotoxins as Two-Faced Janus Proteins.
Study highlights migraine treatment potential
We investigated the effectiveness of botulinum neurotoxins in treating chronic migraines. These proteins, often known for their ability to induce flaccid paralysis, have been found to offer relief for individuals suffering from severe headaches. In essence, they work by blocking the release of acetylcholine, which is known to trigger pain sensations associated with migraines.
The unique aspect of botulinum neurotoxins is their temporary impact. This means that while they can reduce the frequency and severity of migraine episodes, their effects are not permanent, allowing for ongoing treatment options as needed. Our exploration of the various serotypes reveals that they have been approved for use in managing not just migraines but also conditions related to muscle spasticity and excessive sweating.
However, while these toxins present a promising avenue for migraine management, we must remain aware of the potential risks involved. Their poisonous nature makes careful administration essential, and currently, no vaccines exist to counteract their effects. Though the findings suggest a beneficial role for these proteins, the journey of research into their safety and efficacy continues.
The unique aspect of botulinum neurotoxins is their temporary impact. This means that while they can reduce the frequency and severity of migraine episodes, their effects are not permanent, allowing for ongoing treatment options as needed. Our exploration of the various serotypes reveals that they have been approved for use in managing not just migraines but also conditions related to muscle spasticity and excessive sweating.
However, while these toxins present a promising avenue for migraine management, we must remain aware of the potential risks involved. Their poisonous nature makes careful administration essential, and currently, no vaccines exist to counteract their effects. Though the findings suggest a beneficial role for these proteins, the journey of research into their safety and efficacy continues.
Read More
User Reviews
USERS' SCORE
Good
Based on 3 Reviews
8.6
- All Reviews
- Positive Reviews
- Negative Reviews
8.8
Reduced migraine severity
I've been taking these for years as directed by my neurologist to reduce the frequency and severity of my migraines. It took a good year to see the effect, but within three months, I also noticed a decrease in my Chronic Fatigue Syndrome symptoms, which was a delightful surprise. It's essential to maintain the regimen to ensure continued migraine relief.
Read More
8.8
Potential migraine relief
Good quality at a reasonable price from a well-known company. I bought from Amazon and it arrived fresh. I wanted to start taking this for my migraine, which I had forgotten about, as well as for hormone-related afib events. So far, it seems to help; I take it with coconut capsules for added fat. I will update my experience.
Read More
8.8
Effective for visual migraines
Positive results for me, though individual experiences may vary. While rigorous studies are ongoing, I believe it's effective for me. Firstly, it helps with lower back muscle pain, and I have noticed fewer occurrences of visual migraines when taking CoQ10. However, results might differ for others.
Read More
